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Editorial
Transcatheter interventions in valvular heart disease
Intervenções transcateter em doenças cardíacas valvares
In recent years, transcatheter valve implantation and repair have 
shown to be promising treatments for valvular heart disease in patients 
considered inoperable or of high surgical risk. Transcatheter aortic valve 
implantation (TAVI) in patients with severe aortic stenosis has demon-
strated its non-inferiority when compared to surgery in patients with 
considerable surgical risk, and its superiority when compared to medical 
treatment in patients with prohibitive surgical risk. The MitraClipTM, the 
only percutaneous device approved for clinical use in the treatment of 
degenerative or functional severe mitral regurgitation, has shown to be 
non-inferior when compared to surgery in patients with high surgical 
risk, or medical therapy in patients with excessive surgical risk. 
Technical device improvements and advances in the cardiac im-
aging area, especially multislice computed tomography and 
three-dimensional transesophageal echocardiography have been 
essential in obtaining encouraging results and expanding the indi-
cation of transcatheter procedures.
In this context, the current issue of Revista Brasileira de Cardiolo-
gia Invasiva (RBCI) brings two special editorials: one that addresses 
one of the most feared complications of TAVI, coronary obstruction 
during the procedure, the subject of the case report by Furini et al., 
from Hospital São Francisco da Santa Casa de Misericórdia in Porto 
Alegre (RS), and another one that explores the results of MitraClip™ 
use in a pioneering procedure in our country by Brito Jr. et al., from 
Hospital Israelita Albert Einstein, in São Paulo (SP).
Terré, Sergie and Dangas, from Columbia University Medical 
Center and Mount Sinai Medical Center, both in New York, United 
States, in their editorial, perform an actual review of post-TAVI 
coronary obstruction, addressing its incidence, causes, typical 
and atypical clinical manifestations, and consequences. Addition-
ally, they explore the constellation of clinical, anatomical and 
procedural predictors, which play different roles in each case; the 
essential contribution of multislice computed tomography and 
three-dimensional transesophageal echocardiography in identi-
fying high-risk situations for obstruction; and when and how to 
use coronary protection measures. This is a must read and indis-
pensable to all those interested in the subject. 
Attizzani and Tamburino, from Hospital Ferrarotto, University of 
Catania, Catania, Italy, a pioneer group in the use of MitraClip™ in 
that country, in their editorial, recall the still unmet need to offer 
transcatheter procedures for patients with severe mitral regurgita-
tion at high surgical risk, and the sustained benefits of this device in 
the long term, especially regarding quality of life. They recall the 
results of the groundbreaking Everest II study, the several registries 
that have expanded the indications of the procedure for more com-
plex anatomies, as well as the studies that have identified predictors 
of procedural failure and adverse events in the long term. They also 
mention the implantation of balloon-expandable prosthesis in the 
mitral position, a procedure that has been performed in only a few 
cases in human subjects. 
This issue also features original articles from three different insti-
tutions that explore the results of primary percutaneous coronary 
intervention in different subgroups, as well as manuscripts assessing 
several aspects related to the treatment of coronary disease, such as 
the influence of previous statin use on percutaneous coronary inter-
vention outcomes in acute coronary syndrome; the comparison of 
results of a hybrid stent that elutes sirolimus with the results of an 
everolimus-eluting one; and the prevalence, etiology and characteris-
tics of patients with type-2 acute myocardial infarction.
We also have articles showing the results of percutaneous in-
terventions in structural heart diseases, such as the results of 
TAVI in patients with and without left ventricular dysfunction 
and the use of covered stents to treat certain morphological vari-
ations of aortic coarctation or complications ar ising from 
bare-metal stent implantation in this scenario. Two articles con-
tribute to the results in the imaging area, with the validation of a 
new three-dimensional reconstruction model of coronary arter-
ies combining intravascular ultrasound and conventional angiog-
raphy and the comparison of differences between the systolic and 
diastolic dimensions of the aortic valve annulus in CT angiogra-
phy in patients undergoing TAVI. 
Finally, one of the original articles is noteworthy due to the orig-
inality and theme. That is the article by Staico et al., which reports 
the promising results of renal sympathetic denervation in patients 
with implantable cardioverter-defibrillators hospitalized for electri-
cal storm. The procedure significantly reduced the burden of ar-
rhythmias, the over-stimulation and shock in the 30-day follow-up. 
These results complement those from other neuromodulation pro-
cedures, as an emerging strategy for the treatment of arrhythmias 
triggered by sympathetic nervous system alterations.
Enjoy your reading!
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